Literature DB >> 27163296

Slower early response to treatment and distinct expression profile of childhood high hyperdiploid acute lymphoblastic leukaemia with DNA index < 1.16.

Marketa Zaliova1,2, Lenka Hovorkova1,2, Martina Vaskova1,2, Ondrej Hrusak1,2, Jan Stary2, Jan Zuna1,2.   

Abstract

Acute lymphoblastic leukaemias (ALL) with 51-67 chromosomes are defined as high hyperdiploid (HHD) and are generally associated with good prognosis. However, several studies show heterogeneity in HHD ALL and suggest that the favourable prognosis is associated rather with higher ploidy defined by DNA index (DNAi) ≥ 1.16 or with a presence of specific single or combined trisomies. HHD ALL with DNAi < 1.16 are only rarely studied separately. Using single nucleotide polymorphism array, we analysed 89 childhood HHD ALL patients divided into groups with lower (<1.16; n = 34) and higher (≥1.16; n = 55) DNAi. We assessed treatment response, presence of secondary aberrations, mutations in RAS pathway genes and CREBBP and also gene expression profile (GEP) to reveal differences between the two subgroups. Cases with 51-54 chromosomes had DNAi 1.1-1.16 and cases with 55-67 chromosomes had DNAi ≥ 1.16. The groups with lower and higher DNAi had distinct response to early treatment and distinct GEP. The better response of the group with higher DNAi was associated with specific trisomies (trisomy of chromosome 10 or combined with trisomies 4 and/or 17). Our results suggest that cytogenetically defined HHD ALL can in fact be divided into two biologically distinguishable subgroups and that DNAi 1.16 is a relevant value to separate between the two.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27163296     DOI: 10.1002/gcc.22374

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  7 in total

1.  13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking.

Authors:  Minjun Yang; Setareh Safavi; Eleanor L Woodward; Nicolas Duployez; Linda Olsson-Arvidsson; Jonas Ungerbäck; Mikael Sigvardsson; Marketa Zaliova; Jan Zuna; Thoas Fioretos; Bertil Johansson; Karolin H Nord; Kajsa Paulsson
Journal:  Blood       Date:  2020-08-20       Impact factor: 22.113

Review 2.  Recent advances in the management of pediatric acute lymphoblastic leukemia.

Authors:  Jan Starý; Ondřej Hrušák
Journal:  F1000Res       Date:  2016-11-04

3.  Proteogenomics and Hi-C reveal transcriptional dysregulation in high hyperdiploid childhood acute lymphoblastic leukemia.

Authors:  Minjun Yang; Mattias Vesterlund; Ioannis Siavelis; Larissa H Moura-Castro; Anders Castor; Thoas Fioretos; Rozbeh Jafari; Henrik Lilljebjörn; Duncan T Odom; Linda Olsson; Naveen Ravi; Eleanor L Woodward; Louise Harewood; Janne Lehtiö; Kajsa Paulsson
Journal:  Nat Commun       Date:  2019-04-03       Impact factor: 14.919

4.  ERG deletions in childhood acute lymphoblastic leukemia with DUX4 rearrangements are mostly polyclonal, prognostically relevant and their detection rate strongly depends on screening method sensitivity.

Authors:  Marketa Zaliova; Eliska Potuckova; Lenka Hovorkova; Alena Musilova; Lucie Winkowska; Karel Fiser; Jan Stuchly; Ester Mejstrikova; Julia Starkova; Jan Zuna; Jan Stary; Jan Trka
Journal:  Haematologica       Date:  2019-01-10       Impact factor: 9.941

Review 5.  In Utero Development and Immunosurveillance of B Cell Acute Lymphoblastic Leukemia.

Authors:  Nadine Rüchel; Vera H Jepsen; Daniel Hein; Ute Fischer; Arndt Borkhardt; Katharina L Gössling
Journal:  Curr Treat Options Oncol       Date:  2022-03-16

6.  Flow Cytometric DNA Ploidy Analysis in Haemato-Lymphoid Neoplasms: An Analysis of 132 Cases.

Authors:  Nishit Gupta; Aditi Mittal; Tina Dadu; Dharma Choudhary; Anil Handoo
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2022-01-01

Review 7.  New biological and genetic classification and therapeutically relevant categories in childhood B-cell precursor acute lymphoblastic leukemia.

Authors:  Jan Starý; Jan Zuna; Marketa Zaliova
Journal:  F1000Res       Date:  2018-09-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.